Covid-19 man­u­fac­tur­ing roundup: In a push to vac­ci­nate Asia, South Ko­rea ready to make 1B vac­cine avail­able; Mex­i­co's ...

4 years ago
Coronavirus
Manufacturing

BioN­Tech and Takara en­ter li­cense agree­ment for CAR-T; The FDA has freed an­oth­er batch of J&J's Covid-19 vac­cine

4 years ago
Manufacturing

Bridge­Bio adds 3 more in­sti­tu­tions to its ros­ter of col­lab­o­ra­tors; Ex­sci­en­tia lands Gates Foun­da­tion mon­ey for ...

4 years ago
News Briefing

As­traZeneca takes a chance on the STING path­way with F-star

4 years ago
Deals

HHS with­draws Trump-era plan to al­low more per­son­al drug, in­sulin im­ports

4 years ago
FDA+

J&J, Sid Mukher­jee's Vor team up to pair bis­pecifics with en­gi­neered stem cells for blood can­cer

4 years ago
Deals
R&D

A bright fu­ture for LAG-3? Top an­a­lysts see an arms race in the mak­ing, but drug­mak­ers need a bi­ol­o­gy break­through

4 years ago
R&D

Bio­gen nar­rows its Aduhelm la­bel af­ter FDA left the flood­gates open

4 years ago
Pharma
FDA+

A Mubadala-backed biotech is us­ing pa­tient tu­mor tis­sue grown in a petri dish to change pre­ci­sion on­col­o­gy

4 years ago
Financing
AI

In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

4 years ago
FDA+

On­copep­tides says a sec­ond look at its da­ta of­fers a win in head-to-head can­cer tri­al — but key OS flop trig­gers a ...

4 years ago
R&D
FDA+

A uni­corn built on lies? Founders of Sanofi part­ner may face 20 years in prison for al­leged­ly prof­it­ing from stolen ...

4 years ago
People

Eli Lil­ly makes mod­est bet on 'all-in-hu­man' dis­cov­ery out­fit for ALS drugs, deep­en­ing bid in pre­ci­sion neu­rol­o­gy

4 years ago
Deals

Ax­el Hoos, the keep­er of the on­col­o­gy flame at Glax­o­SmithK­line, steps away for his next chal­lenge at tiny Scor­pi­on

4 years ago
People

In­ter­view with Phlow CEO: How soon will es­sen­tial drug man­u­fac­tur­ing come to the US?

4 years ago
Manufacturing

Ar­row­head touts Phase Ib RNAi da­ta for ccR­CC; PureTech lines up PD-1 from BeiGene for up­com­ing com­bo study

4 years ago
News Briefing

Spurring a biotech craze of its own, the UK plots out pub­lic-pri­vate in­vest­ment plan as part of $1B+ in­dus­try ...

4 years ago
Financing

Nu­va­lent joins the IPO par­ty less than 6 months af­ter launch, while Icosavax kicks its 'soc­cer bal­l' VLPs to Nas­daq

4 years ago
Financing

Mod­er­na puts a sea­son­al flu vac­cine in the clin­ic as ex­ecs hope to open chap­ter 2 of their block­buster vac­cine sto­ry

4 years ago
R&D

Af­ter sell­ing its spin­out to Bay­er in a $875M-plus deal, NeRRe Ther­a­peu­tics grabs $28M for some 'un­fin­ished busi­ness'

4 years ago
Financing

FDA shoots down pe­ti­tion to stall gener­ic ver­sions of Bris­tol My­er­s' block­buster chemo Abrax­ane

4 years ago
Pharma
FDA+

Rep. Porter calls on HHS in­spec­tor gen­er­al to in­ves­ti­gate FDA-Bio­gen ties pri­or to Aduhelm's ap­proval

4 years ago
Pharma
FDA+

The top 10 pipeline blowups, set­backs and sna­fus for H1 2021

4 years ago
R&D
Special

WHO signs off on IL-6 drugs to treat se­vere Covid-19 cas­es, reignit­ing pric­ing de­bate

4 years ago
Coronavirus
First page Previous page 679680681682683684685 Next page Last page
A service from the Financial Times